2025 marks a turning point in the clinical development of stem cell therapeutics, as significant regulatory and clinical milestones have been or will be reached in various stem cell programs, including Mesenchymal Stem Cell (MSC)and induced Pluripotent Stem Cell (iPSC)therapies. This progress has been enabled by structured Phase I-III trials and sometimes supported by expedited FDA designations such as regenerative medicine advanced therapy (RMAT) and Fast Track (FDA, 2019). This blog will [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.